免疫疗效生物标志物在鼻咽癌治疗中的预测价值

doi:10.3760/cma.j.cn371439-20201120-00147

摘要/Abstract

摘要：

免疫治疗在复发或转移鼻咽癌患者中客观缓解率达20%~30%,然而获益人群较少。程序性死亡受体-1及其配体-1高表达和(或)肿瘤突变负荷高的鼻咽癌患者,免疫治疗疗效显著;肿瘤微环境生物标志物尤其是肿瘤浸润淋巴细胞,种类丰富,在不同EB病毒状态的鼻咽癌中表达不同,可预测鼻咽癌患者的免疫治疗反应;其他免疫疗效生物标志物如错配修复缺陷在鼻咽癌中发生率较低,预测作用受限。联合检测不同种类免疫疗效预测生物标志物有助于筛选免疫治疗获益人群。

关键词: 鼻咽肿瘤, 免疫疗法, 生物标记, 肿瘤

Abstract:

Immunotherapy has achieved objective response rates of 20%-30% in patients with recurrent or metastatic nasopharyngeal carcinoma, but fewer people are benefiting. Studies have shown that patients with nasopharyngeal carcinoma carrying high expression of programmed death-1/programmed death-ligand 1 and/or high tumor mutation burden have a significant response to immunotherapy. Biomarkers of the tumor microenvironment, especially tumor infiltrating lymphocyte, are abundant in nasopharyngeal carcinoma, varying from different Epstein-Barr virus states, which can also play a predictive role of immunotherapy efficacy. Other biomarkers, such as mismatch repair-deficient, have a low incidence in nasopharyngeal carcinoma and limited predictive power. Combined detection of different types of immunotherapeutic biomarkers is more helpful to identify suitable populations for immunotherapy.

Key words: Nasopharyngeal neoplasms, Immunotherapy, Biomarkers, tumor

罗文肖, 吴德华, 蔡隆梅. 免疫疗效生物标志物在鼻咽癌治疗中的预测价值[J]. 国际肿瘤学杂志, 2021, 48(12): 743-746.

Luo Wenxiao, Wu Dehua, Cai Longmei. Prognostic values of immune efficacy biomarkers in the treatment of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2021, 48(12): 743-746.

参考文献 32

[1]	Sun XS, Liu SL, Luo MJ, et al. The association between the deve-lopment of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012[J]. Int J Radiat Oncol Biol Phys, 2019,105(3):581-590. DOI: 10.1016/j.ijrobp.2019.06.2549.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016,388(10054):1883-1892. DOI: 10.1016/S0140-6736(16)31388-5.
[4]	Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019,394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7.
[5]	Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017,35(36):4050-4056. DOI: 10.1200/JCO.2017.73.3675.
[6]	Ribas A. Tumor immunotherapy directed at PD-1[J]. N Engl J Med, 2012,366(26):2517-2519. DOI: 10.1056/NEJMe1205943.
[7]	Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity[J]. Nature, 2017,545(7655):495-499. DOI: 10.1038/nature22396.
[8]	Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016,375(18):1767-1778. DOI: 10.1056/NEJMra1514296.
[9]	Barone A, Hazarika M, Theoret MR, et al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma[J]. Clin Cancer Res, 2017,23(19):5661-5665. DOI: 10.1158/1078-0432.CCR-16-0664.
[10]	Pai-Scherf L, Blumenthal GM, Li H, et al. FDA approval sum-mary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond[J]. Oncologist, 2017,22(11):1392-1399. DOI: 10.1634/theoncologist.2017-0078.
[11]	Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1[J]. Oncologist, 2019,24(1):103-109. DOI: 10.1634/theoncologist.2018-0221.
[12]	Chan OS, Kowanetz M, Ng WT, et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer[J]. Oral Oncol, 2017,67:52-60. DOI: 10.1016/j. oraloncology.2017.02.002.
[13]	Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo clinic phase 2 consortium (NCI-9742)[J]. J Clin Oncol, 2018,36(14):1412-1418. DOI: 10.1200/JCO.2017.77.0388.
[14]	Jiang F, Yu W, Zeng F, et al. PD-1 high expression predicts lower local disease control in stage Ⅳ M₀ nasopharyngeal carcinoma[J]. BMC Cancer, 2019,19(1):503. DOI: 10.1186/s12885-019-5689-y.
[15]	Huang ZL, Liu S, Wang GN, et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. Cancer Cell Int, 2019,19:141. DOI: 10.1186/s12935-019-0863-5.
[16]	Lipson EJ, Velculescu VE, Pritchard TS, et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade[J]. J Immunother Cancer, 2014,2(1):42. DOI: 10.1186/s40425-014-0042-0.
[17]	Wang HY, Li F, Liu N, et al. Prognostic implications of a molecular classifier derived from whole-exome sequencing in nasopharyngeal carcinoma[J]. Cancer Med, 2019,8(6):2705-2716. DOI: 10.1002/cam4.2146.
[18]	Ali SM, Yao M, Yao J, et al. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy[J]. Cancer, 2017,123(18):3628-3637. DOI: 10.1002/cncr.30781.
[19]	Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. DOI: 10.1093/annonc/mdz197.
[20]	Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas[J]. Semin Cancer Biol, 2012,22(2):127-136. DOI: 10.1016/j.semcancer.2012.01.002.
[21]	Wang YQ, Chen YP, Zhang Y, et al. Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study[J]. Int J Cancer, 2018,142(12):2558-2566. DOI: 10.1002/ijc.31279.
[22]	Zhu Q, Cai MY, Chen CL, et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes[J]. Oncoimmunology, 2017,6(5):e1312240. DOI: 10.1080/2162402X.2017.1312240.
[23]	Lu J, Chen XM, Huang HR, et al. Detailed analysis of inflamma-tory cell infiltration and the prognostic impact on nasopharyngeal carcinoma[J]. Head Neck, 2018,40(6):1245-1253. DOI: 10.1002/hed.25104.
[24]	Ooft ML, van Ipenburg JA, Sanders ME, et al. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma[J]. J Clin Pathol, 2018,71(3):267-274. DOI: 10.1136/jclinpath-2017-204664.
[25]	Chang CH, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression[J]. Cell, 2015,162(6):1229-1241. DOI: 10.1016/j.cell.2015.08.016.
[26]	Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028[J]. J Clin Oncol, 2019,37(4):318-327. DOI: 10.1200/JCO.2018.78.2276.
[27]	Zhang G, Xu Y, Zhou H. The infiltration of ICOS + cells in nasopharyngeal carcinoma is beneficial for improved prognosis [J]. Pathol Oncol Res, 2020,26(1):365-370. DOI: 10.1007/s12253-018-0509-2.
[28]	Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site-when a biomarker defines the indication[J]. N Engl J Med, 2017,377(15):1409-1412. DOI: 10.1056/NEJMp1709968.
[29]	Chen FM, Zhang YX, Li XF, et al. The prognostic value of deficient mismatch repair in stage Ⅱ-Ⅳa nasopharyngeal carcinoma in the era of IMRT[J]. Sci Rep, 2020,10(1):9690. DOI: 10.1038/s41598-020-66678-3.
[30]	Zhao L, Liao X, Hong G, et al. Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma[J]. Cancer Manag Res, 2019,11:1631-1640. DOI: 10.2147/CMAR.S193878.
[31]	Ueda T, Chikuie N, Takumida M, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab[J]. Acta Otolaryngol, 2020,140(2):181-187. DOI: 10.1080/00016489.2019.1699250.
[32]	Ho WJ, Yarchoan M, Hopkins A, et al. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas[J]. J Immunother Cancer, 2018,6(1):84. DOI: 10.1186/s40425-018-0395-x.